持续应用依布替尼对CLL患者的有效性具有维持作用，因此长期毒性是一个令人担忧的问题。本研究报告了CLL患者接受依布替尼治疗的5年随访情况，重点关注高血压和心血管毒性。对患者特征进行评估，包括血压、心血管疾病、疾病进展和死亡率。单因素 logistic 回归分析评估了患者特征与新发或恶化高血压的关系。使用竞争风险评估高血压结果的发生率。使用 Kaplan-Meier 方法估计生存率。本研究纳入了接受临床试验中依布替尼治疗的300名CLL患者。研究入组时年龄中位数为65岁（范围为29-83岁）。70%的患者为男性，88%为白种人。69%的患者在基线时患有高血压，47%的患者正在接受抗高血压药物治疗。88%的患者出现了复发或难治性CLL。新发和恶化的高血压是常见的，分别发生在68.5%和38%的患者中。16.9%的患者收缩压≥160 mm Hg或舒张压≥100 mm Hg。停用依布替尼后高血压是可逆的。年龄较大、男性、吸烟和慢性肾脏疾病与依布替尼相关高血压有关。基线高血压与依布替尼治疗患者的主要不良心血管事件以及事件自由生存率或总体生存率无关。高血压是接受依布替尼治疗的CLL患者常见的毒性反应，但在大多数患者中可管理。除慢性肾脏疾病外，基线心血管疾病不影响依布替尼相关高血压的发生，并且高血压也不与主要不良心血管事件或生存率有关。依布替尼是CLL患者的有效治疗方法。依布替尼是一种耐受性良好的治疗方法，但在接受依布替尼治疗的患者中，高血压可能发生或加重，其他心血管事件也是使用该药物面临的重要挑战。这在患有心脏病的患者中尤为明显。短期副作用可能会加重心脏病，但长期影响尚不清楚。本研究描述了依布替尼对心脏病和高血压的长期影响。 © 2023美国癌症协会。

Continuous ibrutinib administration is needed to maintain efficacy in patients with chronic lymphocytic leukemia (CLL) and, as such, long-term toxicity is a concern. The authors report the 5-year follow-up of patients with CLL who received treatment with ibrutinib with a focus on hypertension and cardiovascular toxicities.Patient characteristics were assessed, including blood pressure, cardiovascular disease, disease progression, and death. Univariate logistic regression analysis assessed the relation of patient characteristics and the development of new or worsened hypertension. The incidence of hypertensive outcomes was evaluated using competing risk. Survival was estimated using the Kaplan-Meier method.Three hundred patients with CLL who were treated with ibrutinib on clinical trials were included. The median patient age at study enrollment was 65 years (range, 29-83 years). Seventy percent of patients were men, and 88% were Caucasian. Sixty-nine percent of patients had hypertension at baseline, and 47% were on antihypertensive medication. Eighty-eight percent had relapsed or refractory CLL. New-onset and worsening hypertension were common, occurring in 68.5% and 38% of patients, respectively. Systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg was observed in 16.9% of patients. Hypertension was reversible after ibrutinib discontinuation. Older age, male sex, tobacco use, and chronic kidney disease were associated with ibrutinib-related hypertension. Baseline hypertension was not associated with major adverse cardiovascular events in ibrutinib-treated patients nor with event-free or overall survival.Hypertension is a common toxicity in patients with CLL who receive ibrutinib but is manageable in most patients. Other than chronic kidney disease, baseline cardiovascular disease did not affect ibrutinib-related hypertension nor was hypertension associated with major adverse cardiovascular events or survival.Ibrutinib is an effective treatment for patients with chronic lymphocytic leukemia. Ibrutinib is a well tolerated therapy, however hypertension can develop or worsen in patients receiving ibrutinib and other cardiovascular events are significant challenges to the use of this drug. This may be particularly true in patients with heart disease. Short-term side effects may worsen heart disease, but the long-term impact is unknown. The long-term results of ibrutinib on heart disease and hypertension are described.© 2023 American Cancer Society.